Paclitaxel plus bevacizumab for metastatic breast cancer [7]

New England Journal of Medicine

Volumn 358, Issue 15, 2008, Pages 1637-1638

  Haines, Ian E ^a   Miklos, George L Gabor ^b  

^a MONASH UNIVERSITY   (Australia)

^b Secure Genetics Pty Limited   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PACLITAXEL; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DISEASE FREE SURVIVAL; HUMAN; LETTER; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL RATE; SURVIVAL TIME; THERAPY EFFECT; TREATMENT RESPONSE; BREAST TUMOR; DISEASE COURSE; EPIDEMIOLOGY; METHODOLOGY; NOTE; MORTALITY; SURVIVAL;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIAS (EPIDEMIOLOGY); BREAST NEOPLASMS; DISEASE PROGRESSION; HUMANS; PACLITAXEL; RESEARCH DESIGN; QUALITY OF LIFE; SURVIVAL ANALYSIS;

EID: 42049096107     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc080128     Document Type: Letter

References (2)

1. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-76.
2. Haines IE. A positive step forward, but more needed to maximize cost benefits of new-generation cancer therapies. J Clin Oncol 2007;25(25):e31-e32.